logo
Common Viruses May Wake Dormant Breast Cancer Cells, Study Finds

Common Viruses May Wake Dormant Breast Cancer Cells, Study Finds

Yahoo6 days ago
Breast cancer patients who have been in remission for years or even decades may still need to be cautious about respiratory infections.
Some common viruses may re-awaken a very small number of dormant breast cancer cells within our lungs, according to emerging research.
"Dormant cancer cells are like the embers left in an abandoned campfire, and respiratory viruses are like a strong wind that reignites the flames," argues molecular geneticist James DeGregori from the University of Colorado.
Related:
The research began following the COVID-19 pandemic, when DeGregori and his colleagues began to notice a curious uptick in cancer cases.
To find out more, the international team turned to human population studies and mouse models.
They found that patients in remission for cancer in the UK Biobank who tested positive for SARS-CoV-2 later showed a twofold increase in cancer-related death.
"The extent of this increased risk is almost unheard of in epidemiology for cancer," says epidemiologist Roel Vermeulen from Utrecht University in The Netherlands.
"It's a significant effect."
That's not all researchers found, either. Analyzing a separate breast cancer database from the United States, including nearly 37,000 patients, they discovered that a previous SARS-CoV-2 infection was associated with a greater than 40 percent increased risk of metastatic breast cancer in the lungs.
Studies in mice suggest that viruses might be behind the spread.
Influenza and SARS-CoV-2 infections triggered dormant breast cancer cells in mice to proliferate after only days of infection.
Within two weeks, there was "a massive expansion of carcinoma cells into metastatic lesions" by more than 100-fold, write the authors, led by molecular geneticist Shi Chia from the University of Colorado.
"Although species differences warrant caution in interpreting mouse data… collectively, these findings underscore the substantial metastatic risk COVID-19 posed to cancer survivors," warn the team.
For years now, scientists have suspected that some highly common viruses, like the Epstein-Barr Virus (EBV), have the potential to trigger certain cancers.
The human papillomavirus (HPV) is already known to do this. That's why the HPV vaccine has proved so life-changing for millions. It prevents deadly, viral-associated diseases, like cervical cancer.
Since 1936, scientists have been searching for a virus that triggers breast cancer in a similar way, mostly in mice and human population studies.
High-risk viruses have been detected in human breast cancer samples. EBV, for instance, is five times higher in breast cancer tissue than in normal tissue.
But while the idea that viruses may predispose us to cancer is plausible, research in human cells is limited, and the mechanism underlying the disease spread remains undetermined.
The immune system's response to viruses could possibly play a role.
After initial remission, a tiny number of breast cancer cells can remain dormant in lung, bone, and liver tissue.
Sometimes, inflammation can wake these cancer cells up – and viral respiratory infections, like the flu and COVID-19, can cause inflammation.
In the current mouse experiments, the influenza A virus only reawakened dormant cancer cells in the lung if they triggered an increase in inflammatory cytokines, such as IL-6.
The same was true of the coronavirus.
The findings suggest that the immune system's response to viruses breeds the perfect environment for cancer to proliferate.
"What our data suggest is that if you are a cancer patient who has these dormant cells, you may end up living a normal life and dying with these dormant cells, instead of dying because those dormant cells awakened," says DeGregori.
"But if you get a respiratory virus like influenza or COVID, your chance of dying from those dormant cells awakening is much greater."
If that's true, then it will be vital to protect the millions of breast cancer survivors out there who may face an increased risk of relapse if they get sick.
Further research is needed to see if vaccination against influenza or COVID-19 can help.
The study was published in Nature.
Related News
Study Reveals The Shocking Amount of Plastic We Breathe in Every Day
Researchers Identified New Blood Group After 50 Year Mystery
Sleepiness Could Be Triggered by a Power Overload in Our Brain
Solve the daily Crossword
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

China tackles chikungunya virus outbreak with wide range of measures as thousands fall ill
China tackles chikungunya virus outbreak with wide range of measures as thousands fall ill

San Francisco Chronicle​

timean hour ago

  • San Francisco Chronicle​

China tackles chikungunya virus outbreak with wide range of measures as thousands fall ill

TAIPEI, Taiwan (AP) — An outbreak of the chikungunya virus in China has prompted authorities to take preventive measures from mosquito nets and clouds of disinfectant, threatening fines for people who fail to disperse standing water and even deploying drones to hunt down insect breeding grounds. More than 7,000 cases of the disease have been reported as of Wednesday, focused largely on the manufacturing hub of Foshan near Hong Kong, which has reported only one case. Numbers of new cases appear to be dropping slowly, according to authorities. Chikungunya is spread by mosquitoes and causes fever and joint pain, similar to dengue fever, with the young, older people and those with pre-existing medical conditions most at risk. Chinese state television has shown workers spraying clouds of disinfectant around city streets, residential areas, construction sites and other areas where people may come into contact with virus-bearing mosquitos that are born in standing water. Workers sprayed some places before entering office buildings, a throwback to China's controversial hardline tactics used to battle the COVID-19 virus. People who do not empty bottles, flower pots or other outdoor receptacles can be subject to fines of up to 10,000 yuan ($1,400) and have their electricity cut off. The U.S. has issued a travel advisory telling citizens not to visit China's Guangdong province, the location of Donguan and several other business hubs, along with countries such as Bolivia and island nations in the Indian Ocean. Brazil is among the othe rcountries hit hard by the virus. Heavy rains and high temperatures have worsened the crisis in China, which is generally common in tropical areas but came on unusually strong this year. China has become adept at coercive measures that many nations consider over-the-top since the deadly 2003 SARS outbreak. This time, patients are being forced to stay in hospital in Foshan for a minimum of one week and authorities briefly enforced a two-week home quarantine, which was dropped since the disease cannot be transmitted between people. Reports also have emerged of attempts to stop the virus spread with fish that eat mosquito larvae and even larger mosquitos to eat the insects carrying the virus. Meetings have been held and protocols adopted at the national level in a sign of China's determination to eliminate the outbreak and avoid public and international criticism.

HHS beings winding down mRNA vaccine development under BARDA
HHS beings winding down mRNA vaccine development under BARDA

Business Insider

time3 hours ago

  • Business Insider

HHS beings winding down mRNA vaccine development under BARDA

The U.S. Department of Health and Human Services announced the beginning of a coordinated wind-down of its mRNA vaccine development activities under the Biomedical Advanced Research and Development Authority, including the cancellation and de-scoping of various contracts and solicitations. The decision follows a comprehensive review of mRNA-related investments initiated during the COVID-19 public health emergency.'We reviewed the science, listened to the experts, and acted,' said HHS Secretary Robert F. Kennedy, Jr. 'BARDA is terminating 22 mRNA vaccine development investments because the data show these vaccines fail to protect effectively against upper respiratory infections like COVID and flu. We're shifting that funding toward safer, broader vaccine platforms that remain effective even as viruses mutate.' The wind-down affects a range of programs including: Cancellation of BARDA's award to Moderna (MRNA)/UTMB for an mRNA-based H5N1 vaccine; Termination of contracts with Emory University and Tiba Biotech; De-scoping of mRNA-related work in existing contracts with Luminary Labs, ModeX, and Seqirus; Rejection or cancellation of multiple pre-award solicitations, including proposals from Pfizer (PFE), Sanofi Pasteur (SNY), CSL Seqirus, Gritstone, and others, as part of BARDA's Rapid Response Partnership Vehicle and VITAL Hub, and; Restructuring of collaborations with DoD-JPEO, affecting nucleic acid-based vaccine projects with AAHI, AstraZeneca (AZN), and HDT Bio. Elevate Your Investing Strategy:

HHS begins winding down mRNA vaccine development under BARDA
HHS begins winding down mRNA vaccine development under BARDA

Business Insider

time3 hours ago

  • Business Insider

HHS begins winding down mRNA vaccine development under BARDA

The U.S. Department of Health and Human Services announced the beginning of a coordinated wind-down of its mRNA vaccine development activities under the Biomedical Advanced Research and Development Authority, including the cancellation and de-scoping of various contracts and solicitations. The decision follows a comprehensive review of mRNA-related investments initiated during the COVID-19 public health emergency.'We reviewed the science, listened to the experts, and acted,' said HHS Secretary Robert F. Kennedy, Jr. 'BARDA is terminating 22 mRNA vaccine development investments because the data show these vaccines fail to protect effectively against upper respiratory infections like COVID and flu. We're shifting that funding toward safer, broader vaccine platforms that remain effective even as viruses mutate.' The wind-down affects a range of programs including: Cancellation of BARDA's award to Moderna (MRNA)/UTMB for an mRNA-based H5N1 vaccine; Termination of contracts with Emory University and Tiba Biotech; De-scoping of mRNA-related work in existing contracts with Luminary Labs, ModeX, and Seqirus; Rejection or cancellation of multiple pre-award solicitations, including proposals from Pfizer (PFE), Sanofi Pasteur (SNY), CSL Seqirus, Gritstone, and others, as part of BARDA's Rapid Response Partnership Vehicle and VITAL Hub, and; Restructuring of collaborations with DoD-JPEO, affecting nucleic acid-based vaccine projects with AAHI, AstraZeneca (AZN), and HDT Bio. Elevate Your Investing Strategy:

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store